mRNA-3745
Sponsors
Moderna Therapeutics Inc., ModernaTX, Inc.
Conditions
Glycogen Storage DiseaseGlycogen storage disease type 1a (GSD1a)
Phase 1
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
Active, not recruitingNCT05095727
Start: 2022-06-01End: 2026-11-30Updated: 2025-12-15
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension
CompletedCTIS2022-502963-39-00
Start: 2024-06-20End: 2025-10-06Target: 24Updated: 2025-07-30